ConductScience.org, home

Paper41574656

Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis.

Mazariegos Herrera A and 3 others. J Antimicrob Chemother, 2026. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis. Papers, record 41574656. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41574656

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis.
PubMed
Journal
J Antimicrob Chemother
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-10-23
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Mazariegos Herrera AAndreshttps://orcid.org/0009-0009-0397-8761
2Karlsson MOMats O
3Svensson EMElin M
4Dorlo TPCThomas P C

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
PhosphorylcholineMajor topic
Leishmaniasis, VisceralMajor topic
Antiprotozoal AgentsMajor topic
Body WeightMajor topic
Humans
Child
Child, Preschool
Male
Female
Administration, Oral
Adolescent
Infant
Africa, Eastern

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
VR 2022-01251Swedish Research CouncilPubMed

Source PubMed

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in42910531Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis-right-to-reply.https://conductscience.org/library/papers/42910531

Source PubMed

Download CSV of comments and corrections

References44

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137380365Social determinants of visceral leishmaniasis elimination in Eastern Africa.BMJ Glob Health2023https://conductscience.org/library/papers/37380365PubMed
219594530Medication errors: prescribing faults and prescription errors.Br J Clin Pharmacol2009https://conductscience.org/library/papers/19594530PubMed
3120433592000 CDC Growth Charts for the United States: methods and development.Vital Health Stat 112002https://conductscience.org/library/papers/12043359PubMed
422833634Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.J Antimicrob Chemother2012https://conductscience.org/library/papers/22833634PubMed
518519729Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.Antimicrob Agents Chemother2008https://conductscience.org/library/papers/18519729PubMed
622693548Leishmaniasis worldwide and global estimates of its incidence.PLoS One2012https://conductscience.org/library/papers/22693548PubMed
738900786A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh.PLoS Negl Trop Dis2024https://conductscience.org/library/papers/38900786PubMed
823835940Modeling and simulation in clinical pharmacology and dose finding.CPT Pharmacometrics Syst Pharmacol2013https://conductscience.org/library/papers/23835940PubMed
922585212Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.Antimicrob Agents Chemother2012https://conductscience.org/library/papers/22585212PubMed
1025642253Clinical Features and Laboratory Findings of Visceral Leishmaniasis in Children Referred To Children Medical Center Hospital, Tehran, Iran during 2004-2011.Iran J Parasitol2014https://conductscience.org/library/papers/25642253PubMed
1130188978Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial.Clin Infect Dis2019https://conductscience.org/library/papers/30188978PubMed
1230038039Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing.Antimicrob Agents Chemother2018https://conductscience.org/library/papers/30038039PubMed
1340113369Simplifying medicine dosing for children by harmonising weight bands across therapeutic areas.Lancet Child Adolesc Health2025https://conductscience.org/library/papers/40113369PubMed
1427627654Efficacy and Safety of AmBisome in Combination with Sodium Stibogluconate or Miltefosine and Miltefosine Monotherapy for African Visceral Leishmaniasis: Phase II Randomized Trial.PLoS Negl Trop Dis2016https://conductscience.org/library/papers/27627654PubMed
1532780098Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa.J Antimicrob Chemother2020https://conductscience.org/library/papers/32780098PubMed
1623425958Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.Clin Infect Dis2013https://conductscience.org/library/papers/23425958PubMed
1736164254Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.Clin Infect Dis2023https://conductscience.org/library/papers/36164254PubMed
1824170666Therapeutic options for visceral leishmaniasis.Drugs2013https://conductscience.org/library/papers/24170666PubMed
1916817681WHO Child Growth Standards based on length/height, weight and age.Acta Paediatr Suppl2006https://conductscience.org/library/papers/16817681PubMed
2034798033Towards the elimination of visceral leishmaniasis as a public health problem in east Africa: reflections on an enhanced control strategy and a call for action.Lancet Glob Health2021https://conductscience.org/library/papers/34798033PubMed

See all 44 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
40980123Optimization and prioritization of paediatric drugs for visceral leishmaniasis.Front Pediatr2025https://conductscience.org/library/papers/40980123

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41574656

GET https://conductscience.org/api/papers/v1/41574656/references?page=2